IPO Databook: Suzhou Zelgen Biopharmaceuticals (HK) - Aug 2026

103 Views14 Aug 2026 10:12

SUMMARY

Suzhou Zelgen Biopharmaceuticals is an integrated biopharmaceutical company focused on oncology, autoimmune diseases, and hemostasis/hematology, powered by a dual innovation engine.
The company has four commercialized drugs, including Zepsun® and Zepuping, and a pipeline of 10 drug candidates across 29 clinical programs.
Revenue was RMB1,204,390 thousand and net profit RMB640,010 thousand for the six months ended June 30, 2026.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream